Frontiers in Clinical Drug Research - Dementia.

Format:

Book

Author/Creator:

Antonio, José Juan.

Contributor:

Antonio, José Juan, Editor.

Series:

Frontiers in Clinical Drug Research - Dementia

Language:

English

Subjects (All):

Anti-infective agents.

Medical innovations.

Anti-inflammatory agents.

Physical Description:

1 online resource (277 pages)

Edition:

1st ed.

Place of Publication:

Singapore : Bentham Science Publishers, 2021.

Summary:

Among neurodegenerative diseases, those that lead to a state ofdementia are the aim of severalinvestigations. Dementia is a chronic disease the prevalence of whichis increasing worldwide. Thenumber of dementia patients in the world is approximately 50 million,and it is estimated that thenumber of patients will reach 131.5 million by 2050. This increase willbe accompanied by asignificant increase in medical expenditures and other expenses,especially for elderly patients.Therefore, the maintenance cost of dementia in the future is expectedto be quite high. For thisreason, several investigations aim, firstly, to describe the keymechanisms involved in the originof dementia and, secondly, to establish preventive and therapeuticstrategies in order tounderstand and mitigate this debilitating pathology. This volume of Frontiers in Clinical Drug Research -Dementia explores the current comorbidities that cause cognitiveimpairment and the current management alternatives for clinical cases ofdementia. The reviews contributed in these volume will provide readers with acurrent perspective on the subject. The topics covered in this volume include:- Comorbidities inducing mild cognitive impairment - an evaluation ofthe risk caused by some pathological conditions- Tau-targeted therapy in Alzheimer's disease - history and currentstate- Emerging nanotherapeutic strategies in Alzheimer's disease- Implication of dehydroepiandrosterone on dementia related tooxidative stress- Polyphenol compounds as potential therapeutic agents in Alzheimer'sdisease The volume is a timely update on dementia treatment for clinicalphysicians, neurologists, gerontologists, pharmaceutical and medicinal chemistryresearchers, and physiologists.

Contents:

Cover

Title

Copyright

End User License Agreement

Contents

Preface

List of Contributors

Comorbidities Inducing Mild Cognitive Impairment, an Evaluation of the Risk Caused by some Pathological Conditions

Yolanda Cruz1, Alejandra Romo1, Roxana Rodríguez-Barrera1, Almudena Chávez-Guerra1, Macarena Fuentes1 and Antonio Ibarra*, 1

INTRODUCTION

OBESITY AND COGNITIVE IMPAIRMENT

Definition and Epidemiology of Obesity

Etiology

Physiopathology of Cognitive Impairment in Obesity

Diet and Low-Grade Inflammation

Treatment

DIABETES MELLITUS AND MILD COGNITIVE IMPAIRMENT

Definition and Epidemiology of Diabetes Mellitus

Etiology and Physiology of Diabetes Mellitus

Type I Diabetes Mellitus (TIDM)

Type II Diabetes Mellitus (TIIDM)

The Role of Insulin in the Brain

Diabetes and Mild Cognitive Impairment

Therapeutic Alternatives

COGNITIVE IMPAIRMENT CAUSED BY VASCULAR ALTERATIONS

Epidemiology of Cardiovascular Diseases

ETIOLOGY AND PHYSIOPATHOLOGY OF VASCULAR LESIONS

Atherosclerotic Plaque Formation

Endothelial Dysfunction

Hypertension as a Cause of Cardiovascular Risk

Cerebrovascular Accident

Effects Caused by Hypertension

Effects Caused by Cerebrovascular Accidents

Pharmacological and Rehabilitation Alternatives for Cognitive Impairment Caused by Cerebrovascular Accidents

COGNITIVE IMPAIRMENT AFTER SPINAL CORD INJURY

Epidemiology and Demographics (Spinal Cord Injury)

Pathophysiology of Spinal Cord Injury

Vascular Damage after Spinal Cord Injury

Cognitive Impairment After Spinal Cord Injury

Depression and Anxiety

Dementia

Learning and Memory Impairment

CONCLUSION

CONSENT FOR PUBLICATION

CONFLICT OF INTEREST

ACKNOWLEDGEMENTS

REFERENCES.

Tau-Targeted Therapy in Alzheimer's Disease - History and Current State

Anamaria Jurcau1,* and Vharoon Sharma Nunkoo1

HISTORICAL BACKGROUND

NORMAL TAU PROTEIN STRUCTURE AND FUNCTION

The Tau Gene and Tau Isoforms

Tau Protein Structure

Tau Localization

Tau Localization in Neurons

Tau Localization in Glial Cells

Functions of Tau Protein

Post-Translational Modifications of Tau

Tau Phosphorylation

Tau Acetylation

Tau Glycosylation

Tau Ubiquitination

Tau Sumoylation

Tau Methylation

Other Post-translational Modifications of Tau

Tau Clearance

TAUOPATHIES

Tau-Mediated Neurodegeneration

Tau Gene Dysfunction

Tau Aggregation

Tau Truncation

Axonal Transport Impairment in Tauopathies

Nuclear Tau Dysfunction

Tau-Mediated Dendritic Dysfunction

Tau and Mitochondrial Dysfunction

Tau Seeding and Propagation

Amyloid-Beta and Tau

TAU IN THE PATHOGENESIS OF ALZHEIMER'S DISEASE

TAU-TARGETED THERAPY IN ALZHEIMER'S DISEASE

Modulating Tau Phosphorylation

Targeting Tau Acetylation

Targeting Tau Glycosylation

Microtubule Stabilizers

Tau Aggregation Inhibitors

Antisense Oligonucleotides (ASOs)

Phosphodiesterase 4 Inhibitors

Anti-tau Immunotherapy

Anti-tau Active Immunotherapy

Passive Anti-tau Immunotherapy

REFERENCES

Implication of Dehydroepiandrosterone on Dementia Related to Oxidative Stress

Adriane Bello Klein1, Alexandre Castro1, Alex Sander da Rosa Araujo1, Daiane da Rocha Janner2 and Maria Helena Vianna Metello Jacob3,*

The Implication of Aging and Oxidative Stress in Dementia

Dehydroepiandrosterone, Hormonal Derangement, and Dementia

DHEA, What is it?

DHEA as a Neuro-Steroid

DHEA's Receptor

Hormonal Derangement and Dementia.

Aging, Oxidative Stress, Dementia, and Dehydroepiandrosterone

DHEA and Oxidative Stress Mechanisms

DHEA, Aging and Dementia

Emerging Nanotherapeutic Strategies in Alzheimer's Disease

Soheila Montazersaheb1, Elham Ahmadian2, Solmaz Maleki Dizaj3, Yalda Jahanbani4, Soodabeh Davaran4, Irada Huseynova5, Cumali Keskin6, Renad I. Zhdanov7,8, Rovshan Khalilov7,9,10 and Aziz Eftekhari7,11,*

NEURON TARGETING IN AD

NANOTECHNOLOGY IN AD THERAPY

Pathogenesis of AD

Nanotechnology-based Treatments for Alzheimer's Disease

Polymeric Nanoparticles

Lipid Nanoparticles

Other Nanoparticles

NANOTECHNOLOGY IN AD DIAGNOSIS

Biomarkers in AD Diagnosis

DNA-Nanoparticle Conjugates

Magnetic Nanoparticles

NIAD-4

Quantum Dots

FUTURE PERSPECTIVES

Polyphenol Compounds as Potential Therapeutic Agents in Alzheimer's Disease

Érika Paiva de Moura1, Alex France Messias Monteiro1, Natan Dias Fernandes1, Herbert Igor Rodrigues de Medeiros1, Igor José dos Santos Nascimentos2, Marcus Tullius Scotti1, Francisco Jaime Bezerra Mendonça Júnior3, Edeildo Ferreira da Silva-Júnior*, 2 and Luciana Scotti1,4

POLYPHENOLS WITH ANTI-ALZHEIMER ACTIVITIES

Anti-Amyloid Aggregation Agents

Cholinesterase inhibitors

BACE-1 Inhibitors

Neuroprotectors

Kinases Inhibitors and Anti-Tau Pathology Agents

Multi-Target Agents Against Alzheimer's Disease

Subject Index

Back Cover.

Notes:

Description based on publisher supplied metadata and other sources.

ISBN:

9789815039474

9815039474

OCLC:

1290023184